Inoviq Ltd (DE:EGQ0)
FRANKFURT:EGQ0
EGQ0 Stock Chart & Stats
€0.21
-€0.02(-5.23%)
At close: 4:00 PM EST
€0.21
-€0.02(-5.23%)
Day’s Range― - ―
52-Week Range€0.16 - €0.23
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€27.02M
Enterprise Value€24.43M
Total Cash (Recent Filing)€13.80M
Total Debt (Recent Filing)€270.31K
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity ratio of 0.0225 signals minimal financial leverage, reducing solvency and refinancing risk. Over a multi-month horizon this preserves strategic optionality for R&D spend, partnership deals, or selective capital raises without heavy interest burdens, aiding stability while commercialisation progresses.
Focused Exosome Diagnostics PlatformInoviq’s concentrated business model on exosome isolation, characterisation and cancer diagnostics targets structural demand in early-detection and biomedical research. A clear product/service and partnering revenue mix supports recurring and milestone-based income streams, which can sustain growth as adoption of liquid biopsy tools increases.
Cash-flow To Earnings AlignmentA free cash flow to net income ratio slightly above 1 indicates reported earnings roughly translate into cash, implying reasonable cash conversion mechanics. If revenue stabilization occurs, this alignment can support durable cash generation improvements and reduce the need for continual external funding over ensuing months.
Bears Say
Declining Revenue And MarginsA -17.20% revenue decline coupled with negative gross, EBIT and net margins points to persistent top-line contraction and weak unit economics. Over a 2-6 month horizon, this undermines reinvestment in commercialisation and R&D, impairs scaling potential, and makes achieving sustainable profitability more challenging.
Negative Return On EquityA -41.47% ROE indicates the company is destroying shareholder value and not effectively deploying equity capital. Persistently negative ROE over months signals poor capital allocation or operating losses that will pressure future fundraising terms and limit internal financing for product rollouts or strategic partnerships.
Negative Operating And Free Cash FlowsConsistent negative operating and free cash flows show the business currently consumes cash to run operations. This structural cash burn reduces runway and increases reliance on external financing, which can force strategic trade-offs, slow commercialisation timelines, or dilute shareholders in the medium term.
Inoviq Ltd News
EGQ0 FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest stock price was €0.16 and its highest was €0.23 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is €27.02M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in DE:EGQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EGQ0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €72.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.47%
12-Months-Change
Fundamentals
Return on Equity
-37.14%
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---